SEARCH RESULTS

330731 RESULTS

PAPER Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C,

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

N Engl J Med. 2004 Mar 11;350(11):1081-92. PubMed: 15014181

PAPER Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD,

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

N Engl J Med. 2005 Oct 20;353(16):1659-72. PubMed: 16236737

Drug Discovery for Neurodegenerative Disease 2007

CONFERENCE COVERAGE SERIES New York: Can Academia and Industry Work Hand-in-Glove? New York: Back to School—R and D in Academia New York: So Many Targets, So Little Time New York: Better Living Through Chemistry? New York: The Nose, Your Magic Portal? Drug Discovery for Neurodegene

Clinical Trial Data: Fit for Public Consumption

COMMUNITY NEWS 2007-03-13 Community News This week, two independent groups of academic researchers call for more transparency in the conduct of clinical trials. One focuses on the structure of industry-academic partnerships in clinical trials, while the other argues for a more ope

New York: The Nose, Your Magic Portal?

CONFERENCE COVERAGE 2007-03-13 Conference Coverage William Frey of the University of Minnesota in Minneapolis believes in the BBB. Rather than dealing with the pesky obstacle, though, he’s trying an end run around it. His route of choice is the nose, where his work suggests one gains a

MAP2a + MAP2b

ANTIBODY monoclonal manufacturer Cat# MAB378 immunogen = bovine MAP2 liquid, ascites detects 300kDa MAP2a & 280 kDa MAP2b only others not tested IgG<sub>1</sub> MAPs Chemicon and Upstate are Millipore Mouse Amphibian (various) Bovine Quail Human Mo

MAP2 (5F9)

ANTIBODY monoclonal 5F9 manufacturer Cat# 05-346 immunogen = purified rat brain MAP2 protein-G purified liquid, phosphate buffer, azide MAP2 others not tested IgG<sub>1</sub> MAPs Upstate and Chemicon are Millipore Mouse Rabbit Human Mouse Rat MAP2 htt

Current Filters

  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE